Brokerages expect Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) to announce $9.47 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Nabriva Therapeutics’ earnings. The lowest sales estimate is $8.53 million and the highest is $10.40 million. Nabriva Therapeutics reported sales of $8.24 million in the same quarter last year, which indicates a positive year-over-year growth rate of 14.9%. The business is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Nabriva Therapeutics will report full year sales of $41.31 million for the current fiscal year, with estimates ranging from $39.32 million to $43.29 million. For the next fiscal year, analysts expect that the company will report sales of $71.73 million, with estimates ranging from $67.25 million to $76.21 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Nabriva Therapeutics had a negative return on equity of 82.07% and a negative net margin of 137.52%. During the same quarter last year, the business earned ($0.53) EPS.
NASDAQ NBRV opened at $0.19 on Wednesday. The firm has a market capitalization of $120.59 million, a price-to-earnings ratio of -0.20 and a beta of 1.57. The company has a current ratio of 4.01, a quick ratio of 2.94 and a debt-to-equity ratio of 0.09. Nabriva Therapeutics has a 1 year low of $0.18 and a 1 year high of $2.32. The firm’s 50 day simple moving average is $0.34 and its 200 day simple moving average is $0.52.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBRV. FMR LLC boosted its holdings in Nabriva Therapeutics by 77.0% during the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock valued at $7,958,000 after acquiring an additional 1,418,800 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Nabriva Therapeutics during the 1st quarter worth $179,000. GSA Capital Partners LLP acquired a new position in Nabriva Therapeutics during the 4th quarter valued at about $214,000. Renaissance Technologies LLC increased its holdings in shares of Nabriva Therapeutics by 116.3% in the fourth quarter. Renaissance Technologies LLC now owns 471,300 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 253,415 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Nabriva Therapeutics during the fourth quarter worth about $125,000. Institutional investors own 1.55% of the company’s stock.
About Nabriva Therapeutics (Get Rating)
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- 3 Defensive Consumer Stocks Worth Shopping For
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.